Hepatitis C

Disease-a-Month

Volumn 60, Issue 5, 2014, Pages 201-212

  Chan, Juliana ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON; PLACEBO; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR;

ANEMIA; ANOREXIA; ANTIVIRAL THERAPY; ANXIETY DISORDER; ARTHRALGIA; BLOOD TRANSFUSION; CHILL; CLINICAL TRIAL; COUGHING; DEPRESSION; DIABETES MELLITUS; DIARRHEA; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTRIGLYCERIDEMIA; INJECTION SITE REACTION; INSOMNIA; INTRAVENOUS DRUG ABUSE; JAUNDICE; LIVER CIRRHOSIS; LIVER FIBROSIS; MALAISE; MENTAL DISEASE; MYALGIA; NAUSEA; NEUTROPENIA; PHOTOSENSITIVITY; PRURITUS; RASH; REVIEW; SEXUAL INTERCOURSE; TATTOO; TELEHEALTH; TERATOGENICITY; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS TRANSMISSION;

ADULT; AGE DISTRIBUTION; ANTI-HIV AGENTS; COMMUNICABLE DISEASE CONTROL; DISEASE MANAGEMENT; FEMALE; HEPATITIS C; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; INCIDENCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NEEDS ASSESSMENT; PRISONERS; PRISONS; RIBAVIRIN; RISK ASSESSMENT; SEX DISTRIBUTION; SULFONAMIDES; TELEMEDICINE; TREATMENT OUTCOME; UNITED STATES; URIDINE MONOPHOSPHATE; YOUNG ADULT;

EID: 84901360401     PISSN: 00115029     EISSN: 15578194     Source Type: Journal    
DOI: 10.1016/j.disamonth.2014.04.002     Document Type: Review

References (38)

1. World Health Organization. Hepatitis C: WHO fact sheet N° 164. 2013 Accessed 22.02.14. http://www.who.int/mediacentre/factsheets/fs164/en/index.html.
2. Center for Disease Control. Hepatitis C FAQs for health professionals. 2012 Accessed 22.02.14. http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm%23section1.
3. Chak E., Talal A.H., Sherman K.E., Schiff E.R., Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011, 31(8):1090-1101.
4. Moyer V.A. Screening for hepatitis C virus infection in adults: US preventive services task force recommendation statement. Ann Intern Med 2013, 159(5):349-357.
5. Weinbaum C., Lyerla R., Margolis H.S. Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003, 52(RR-1):1-36.
6. Beck AJ, Maruschak LM. Hepatitis testing and treatment in state prisons. US Department of Justice, Office of Justice Programs, Bureau of Statistics. 2004 Accessed 22.02.14. http://www.bjs.gov/content/pub/pdf/httsp.pdf.
7. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49(4):1335-1374.
8. Ghany M.G., Nelson D.R., Strader D.B., Thomas D.L., Seeff L.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the study of liver diseases. Hepatology 2011, 54(4):1433-1444.
9. Klevens R.M., Hu D.J., Jiles R., Holmberg S.D. Evolving epidemiology of hepatitis C virus in the United States. Clin Infect Dis 2012, 55(suppl 1):S3-S9.
10. Smith B.D., Morgan R.L., Beckett G.A., et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012, 61(RR-4):1-32.
11. Mahajan R., Liu S.J., Klevens R.M., Holmberg S.D. Indications for testing among reported cases of HCV infection from enhanced hepatitis surveillance sites in the United States, 2004-2010. Am J Public Health 2013, 103(8):1445-1449.
12. Federal Bureau of Prisons. Evaluation and treatment of hepatitis C and cirrhosis. Clinical practice guidelines. 2012 Accessed 22.02.14. http://www.hepcassoc.org/pdf/2012/mar-federal-guidlines.pdf.
13. Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep 2013, 62(18):362-365. Centers for Disease Control and Prevention (CDC).
14. Smith D.B., Bukh J., Kuiken C., et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014, 59(1):318-327.
15. American Association for the Study of Liver Diseases and Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Initial treatment of HCV infection in patients starting treatment. Accessed 22.02.14. http://www.hcvguidelines.org/full-report/initial-treatment-hcv-infection-patients-starting-treatment.
16. American Association for the Study of Liver Diseases and Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Retreatment of persons in whom prior therapy has failed. Accessed 22.02.14. http://www.hcvguidelines.org/full-report/retreatment-persons-whom-prior-therapy-has-failed.
17. Chen J., Florian J., Carter W., et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013, 144(7):1450-1455.
18. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry chronic hepatitis C virus infection: developing direct-acting antiviral drugs for treatment. Draft guidance. 2013 Accessed 22.02.14. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM225333.pdf.
19. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2014, 60(2):392-420. European Association of the Study of the Liver.
20. Sovaldi [package insert]. Foster City, CA: Gilead Sciences; 2013.
21. Olysio [package insert]. Titusville, NJ: Janssen Therapeutics; 2013.
22. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368(20):1878-1887.
23. Jacobson I., Ghalib R.M., Rodriguez-Torres M., et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: the COSMOS study. Hepatology 2013, 58:1379A.
24. Jacobson I., Dore G.J., Foster G.R., et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial. J Hepatol 2013, 58:1425A.
25. Manns M., Marcellin P., Fred Poordad F.P., et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-2, a phase III trial. J Hepatol 2013, 58:1413A.
26. Lenz O., Verbinnen T., Lin T.I., et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010, 54(5):1878-1887.
27. Jacobson I.M., Gordon S.C., Kowdley K.V., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013, 368(20):1867-1877.
28. Zeuzem S., Dusheiko G.M., Salupere R. Sofosbuvir and ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. Hepatology 2013, 58:1085A.
29. Moreno C, Hezode C, Marcellin P, et al. Simeprevir with peginterferon/ribavirin in treatment-naive or -experienced patients with chronic HCV genotype 4 infection: a phase III study. 14th European AIDS Conference;2013 [Abstract PS9/6].
30. Pegasys [package insert]. San Francisco, CA: Genentech USA, Inc; 2013.
31. Copegus [package insert]. San Francisco, CA: Genentech USA, Inc; 2013.
32. Incivek [package insert]. Cambridge, MA: Vertex; 2013.
33. Victrelis [package insert]. Whitehouse Station, NJ; 2014.
34. Rice J.P., Burnett D., Tsotsis H., et al. Comparison of hepatitis C virus treatment between incarcerated and community patients. Hepatology 2012, 56(4):1252-1260.
35. Allen S.A., Spaulding A.C., Osei A.M., Taylor L.E., Cabral A.M., Rich J.D. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med 2003, 138(3):187-190.
36. Chew K.W., Allen S.A., Taylor L.E., Rich J.D., Feller E. Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C. J Clin Gastroenterol 2009, 43(7):686-691.
37. Iacomi F., Iannicelli G., Franceschini A., et al. HCV infected prisoners: should they be still considered a difficult to treat population?. BMC Infect Dis 2013, 13:1-7.
38. Tan J.A., Joseph T.A., Saab S. Treating hepatitis C in the prison population is cost-saving. Hepatology 2008, 48(5):1387-1395.